Lipella Pharmaceuticals Files 8-K on Corporate Changes
Ticker: LIPO · Form: 8-K · Filed: Apr 9, 2025 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, bylaws
TL;DR
Lipella Pharma (LIPAF) filed an 8-K detailing corporate changes and modifications to security holder rights.
AI Summary
Lipella Pharmaceuticals Inc. filed an 8-K on April 9, 2025, reporting material modifications to security holder rights and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Pittsburgh, PA.
Why It Matters
This filing indicates significant corporate actions and potential changes in the rights of Lipella Pharmaceuticals' security holders, which could impact investors.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate documents can introduce uncertainty and potential risks for investors.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Pittsburgh, PA (location) — Principal executive offices
- April 9, 2025 (date) — Date of report
- April 8, 2025 (date) — Earliest event reported
FAQ
What specific material modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the excerpt.
What amendments were made to Lipella Pharmaceuticals' articles of incorporation or bylaws?
The filing states that amendments to the articles of incorporation or bylaws were made, but the specific nature of these amendments is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 8, 2025.
What is the principal business address of Lipella Pharmaceuticals Inc.?
The principal executive offices of Lipella Pharmaceuticals Inc. are located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
What is the SIC code for Lipella Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Lipella Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2025 regarding LIPELLA PHARMACEUTICALS INC. (LIPO).